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Abstract
Background: Premature Ovarian Failure (POF), defined as the development of
hypergonadotropic amenorrhea before the age of 40 years, occurs in about 1% of all women. Other
than karyotype abnormalities, very few genes are known to be associated with this ovarian
dysfunction. Recently, in seven patients who presented with POF and white matter abnormalities
on MRI (ovarioleukodystrophy) eight mutationswere found in EIF2B2, 4 and 5.
Methods: To further test the involvement of known mutations of EIF2B genes in POF, we
screened 93 patients with POF who did not have identified leukodystrophy or neurological
symptoms. We evaluated these eight mutations and two additional mutations that had been found
in patients with milder forms of eIF2B-related disorders. We used restriction enzymes and direct
sequencing.
Results: None of the known mutations in EIF2B genes, either homozygous or heterozygous, were
identified in our 93 patients with pure 46,XX POF. The upper 95 % confidence limit of the
proportion 0/93 is 3.2%.
Conclusions: We conclude that eIF2B mutations, already described in cases of POF associated
with white matter abnormalities, are an uncommon cause of pure spontaneous premature ovarian
failure.
Background
Premature Ovarian Failure (POF) can present as a primary
or secondary amenorrhea and is associated with elevated
gonadotropins before 40 years of age. POF affects 1% of
all women and occurs in 0.1% before the age of 30 years
[1]. POF has been associated with karyotype abnormali-
ties, including various X chromosome aberrations such as
Turner syndrome, which causes depletion of ovarian folli-
cles during development [2]. While conditions such as
autoimmune diseases are also associated with POF, the
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cause is unknown in about 90 % of cases. However, since
many affected women have a family history of the condi-
tion, predisposition to POF may be inherited [3]. To date,
mutations associated with POF have been identified in a
small number of genes [4], including those encoding the
inhibin alpha [5], the FSH receptor [6], the LH/choriogo-
nadotrophin receptor [7], and the forkhead transcription
factor 2 [8]. No more than 10% of women with ovarian
failure have mutations in these different genes [8].
Recently three of the five EIF2B genes (EIF2B2, 4 and 5)
were reportedly involved in seven patients who presented
with POF and white matter abnormalities on MRI (ovari-
oleukodystrophy) [9]. These genes encode the five subu-
nits of the eucaryotic initiation factor 2B (eIF2B alpha to
epsilon), which is involved in the first step of protein syn-
thesis. eIF2B-related disorders include a large group of
phenotypes with a recognizable MRI pattern but different
clinical severities. The clinical spectrum can range from a
rapid course leading to death in severe congenital forms to
asymptomatic MRI findings in adult patients [10,11].
Ovarioleukodystrophy might present in a phase without
neurological symptoms and an apparently isolated form
of POF [9]. Therefore, we screened a series of 93 patients
with apparently pure, karyotypically normal POF for
mutations in EIF2B genes.
Methods
Selection of patients with premature ovarian failure
In the current study, we evaluated the presence of EIF2B
mutations in 93 unrelated and well-characterized women
with POF. An institutional review board approved the
study and all participants gave a written informed con-
sent. Referring physicians made the diagnosis of prema-
ture ovarian failure based on the following criteria:
development of at least 4 months of amenorrhea before
age 40 associated with two serum FSH levels in the meno-
pausal range. Women with premature ovarian failure as a
result of surgery, radiation, chemotherapy, or known
karyotype abnormalities were not included in the study.
There were 6 Asians, 12 Blacks, 4 Hispanics and 71 Cauca-
sians. The median age at the onset of menstrual irregular-
ity was 24.5 years (range 13 to 39). Eighteen women had
a family history of POF. All women underwent a history
and physical examination and laboratory screening to
confirm the diagnosis of POF and all had a normal karyo-
type. None of the women had evidence of a neurological
disorder.
EIF2B mutations screening
Genomic DNA was extracted from peripheral blood using
standard procedures.
The exons of the genes EIF2B2, 4 and 5 which contain
mutations found in POF patients or in milder forms of
eIF2B-related disorders were amplified by the polymerase
chain reaction (PCR) as previously described (Table
1)[11].
Nine mutations were tested by restriction enzymes
directly on PCR products (Table 2): 500 ng of PCR prod-
ucts were incubated with 1 unit of specific restriction
enzyme from Biolabs® Inc. for 90 minutes, according to
the supplier's instructions. Restriction fragments were
analyzed by standard acrylamide gel electrophoresis.
The C583T (R195C) mutation in the EIF2B5 gene was
tested by direct sequencing of exon 4 as previously
described [11].
Table 1: Sequences of PCR primers used and their PCR conditions.
Nucleotide change tested (gene) Primers sequences (5'-3') PCR conditions
C512T (EIF2B2), C547T (EIF2B2) F: GCAAAACCGTTCTTAC
R: CCTACCCATCTCTCGTTTAT
PCR preparation: 1.5 mM MgCl2, 0.225 mM dNTP, 0.8 µM primers, 100 ng primers, 1 unit AmpliTaq 
Gold™(Applied Biosystems), 1X Taq buffer.
607–612del/insTG (EIF2B2), A638G (EIF2B2) F: GGAAATTATGTGCTGGATATG
R: ACTTTATTCTCTCACCGTGGAT
P243L (EIF2B4) F: ATGCTCAAGCTCCCTTTCAA
R: CTTCACAACTTACAAAGCCT
R374C (EIF2B4) F: ATTCAAGCACCTGGCATGAT
R: CGCTGCACTCCATCCTTATC
PCR reaction: 95°C 12 min, 35 cycles (94°C 30 s, 55°C 30 
s, 72°C 45 s), 72°C 10 min, 4°C.
T1393C (EIF2B4), T1465C (EIF2B4) F: TGTCCTGTAAGTAGGGGACCTT
R: AAGGGGTTGTGAAGTCTGGA
G338A (EIF2B5), C583T (EIF2B5) F: GAGAAGGACTGTGAGTGCTGA
R: GCCTTCTAAGGGGACAATAAC
F: forward primer, R: reverse primer
BMC Women's Health 2004, 4:8 http://www.biomedcentral.com/1472-6874/4/8
Page 3 of 4
(page number not for citation purposes)
Results
None of the eight mutations already described in ovario-
leukodystrophy were detected in our 93 patients with
pure 46,XX POF, neither in a homozygous nor in a heter-
ozygous state. In addition, the mutations C728T and
C1120T (EIF2B4) described in milder forms of eIF2B-
related disorders were not found in this series of 93
patients with POF. The upper 95 % confidence limit of the
proportion 0/93 is 3.2%.
Discussion
eIF2B-related disorders include a large group of pheno-
types with different clinical severities. Individuals can be
classified into three clinical groups according to their age
at disease onset: <2 years (group 1), 2 to 5 years (group 2)
and > 5 years (group 3) [11]. Group 3 corresponds to indi-
viduals with the milder form of the disease, including the
six families (seven patients) already described presenting
with ovarioleukodystrophy [9].
In these six eIF2B-mutated families, neurological symp-
toms with abnormalities of the cerebral white matter on
MRI were associated with primary or secondary amenor-
rhea due to POF [9]. A correlation was observed between
the age of onset of the neurological deterioration and the
severity of the ovarian failure, suggesting a common
pathophysiological pathway [9].
The mutated eIF2B may be responsible for both increased
apoptosis of ovarian follicles leading to POF, and a defect
in glial cell development causing abnormal formation of
white matter structures. In ovarioleukodystrophy, a phase
of amenorrhea without neurological symptoms can be
observed, suggesting that an apparently isolated case of
POF might be due to EIF2B mutations. In the present
study, we tested for EIF2B mutations a series of 93 patients
with pure, karyotypically normal POF without identified
signs of cerebral dysfunction.
In eIF2B-related disorders, a correlation exists between
genotype and disease onset [11]. The mutations G338A
(EIF2B5 gene) and A638G (EIF2B2 gene) are found in
71% of families with late onset forms of eIF2B-related dis-
orders (group 3) [11]. In ovarioleukodystrophy, 4/6 fam-
ilies have a G338A or A638G mutation in a heterozygote
or a homozygote state. Thus, to further evaluate involve-
ment of eIF2B mutations in apparently isolated cases of
POF, we restricted our screening to the 10 mutations asso-
ciated with the late onset form (group 3) of eIF2B-related
disorders. In the present series of 93 patients with pure,
karyotypically normal POF, no mutations were detected,
suggesting a low frequency of EIF2B mutations in women
with POF who have no apparent neurological signs.
Table 2: EIF2B2, 4 and 5 mutations tested with restriction enzymes.
Mutation tested: 
nucleotides 
changes (amino 
acid changes)
Mutated gene Restriction 
enzyme used
PCR product 
size 
(base pairs)
Restriction profile (number of restriction fragments: their size in base pairs)
No mut* Het mut* Hom mut*
C512T (S171F) EIF2B2 Hpy188III 251 4 fragments: 51, 29, 16 
and 155 bp.
5 fragments: 51, 29, 16, 
155 and 171 bp.
3 fragments: 51, 29 and 
171 bp.
607–612del/insTG 
(M203fs)
EIF2B2 HphI 313 2 fragments: 310 and 3 
bp.
4 fragments: 310, 142, 
164 and 3 bp.
3 fragments: 142, 164 
and 3 bp.
C547T (R183stop) EIF2B2 EcoNI 253 2 fragments: 120 and 
133 bp.
4 fragments: 120, 133, 
14 and 119 bp.
3 fragments: 120, 14 
and 119 bp.
A638G (E213G) EIF2B2 BsmAI 313 2 fragments: 153 and 
160 bp.
3 fragments: 313, 160 
and 153 bp.
1 fragment: 313 bp
P243L (C728T) EIF2B4 AciI 612 3 fragments: 353, 223 
and 36 bp.
4 fragments: 576, 353, 
223 and 36 bp.
2 fragments: 576 and 36 
bp.
R374C (C1120T) EIF2B4 HpyCH4IV 640 2 fragments: 447 and 
193 bp.
3 fragments: 640, 447 
and 193 bp.
1 fragment: 640 bp.
T1393C (C465R) EIF2B4 BsrDI 694 3 fragments: 368, 32 
and 294 bp.
4 fragments: 368, 32, 
294 and 326 bp.
2 fragments: 368 and 
326 bp.
T1465C (Y489H) EIF2B4 NlaIII 707 3 fragments: 109, 310 
and 288 bp.
5 fragments: 109, 310, 
288, 57 and 231 bp.
4 fragments: 109, 310, 
57 and 231 bp.
G338A (R113H) EIF2B5 Fnu4HI 800 3 fragments: 115, 633 
and 52 bp.
4 fragments: 115, 633, 
52 and 748 bp.
2 fragments: 748 and 52 
bp.
* No mut: no mutation; Het mut: heterozygous mutation; Hom mut: homozygous mutation.
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Women's Health 2004, 4:8 http://www.biomedcentral.com/1472-6874/4/8
Page 4 of 4
(page number not for citation purposes)
Conclusions
For patients presenting with POF without neurological
signs or MRI abnormalities, the routine screening of the
EIF2B mutations is not clinically indicated.
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